Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.
复制标题
DOI：
10.1038/s41587-022-01232-2
复制
发表时间：
2022-08
影响因子：
46.9
通讯作者：
Georgiev, Ivelin S.
中科院分区：
文献类型：
--
作者：
Shiakolas, Andrea R.;Kramer, Kevin J.;Johnson, Nicole, V;Wall, Steven C.;Suryadevara, Naveenchandra;Wrapp, Daniel;Periasamy, Sivakumar;Pilewski, Kelsey A.;Raju, Nagarajan;Nargi, Rachel;Sutton, Rachel E.;Walker, Lauren M.;Setliff, Ian;Crowe, James E.;Bukreyev, Alexander;Carnahan, Robert H.;McLellan, Jason S.;Georgiev, Ivelin S.
尽管几种针对严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)的单抗已被批准用于治疗冠状病毒病2019年(新冠肺炎)，但开发通常效率低下，铅的产生往往需要生产和测试大量候选抗体。在这里，我们报告了靶标配体阻断与先前描述的B细胞受体测序方法(通过测序将B细胞受体与抗原特异性联系起来(LIBRA-SEQ))的集成，使得能够快速有效地识别多种中和单抗，这些单抗可以阻止SARS-CoV-2刺突蛋白(S)与血管紧张素转换酶2(ACE2)的结合。靶标配体阻断和高通量抗体测序的结合有望增加旨在发现新的中和抗体的程序的吞吐量。配基阻断的B细胞受体测序加快了中和抗体的发现。
Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies. B cell receptor sequencing with ligand blocking speeds up neutralizing antibody discovery.
登录
查看更多内容
影响因子：
56.9
作者：
Hsieh, Ching-Lin;Goldsmith, Jory A.;McLellan, Jason S.
通讯作者：
McLellan, Jason S.
影响因子：
48
作者：
Punjani, Ali;Rubinstein, John L.;Brubaker, Marcus A.
通讯作者：
Brubaker, Marcus A.
影响因子：
3
作者：
Mastronarde, DN
通讯作者：
Mastronarde, DN
SARS-CoV-2 感染引起的人类中和抗体
影响因子：
64.8
作者：
Ju, Bin;Zhang, Qi;Zhang, Linqi
通讯作者：
Zhang, Linqi
影响因子：
64.5
作者：
Suryadevara N;Shrihari S;Gilchuk P;VanBlargan LA;Binshtein E;Zost SJ;Nargi RS;Sutton RE;Winkler ES;Chen EC;Fouch ME;Davidson E;Doranz BJ;Chen RE;Shi PY;Carnahan RH;Thackray LB;Diamond MS;Crowe JE Jr
通讯作者：
Crowe JE Jr